Pazopanib

Nat Rev Drug Discov. 2010 Jan;9(1):17-8. doi: 10.1038/nrd3073.

Abstract

In October 2009, pazopanib (Votrient; GlaxoSmithKline)--a multikinase inhibitor with targets that include vascular endothelial growth factor receptors--was approved by the US FDA for the treatment of advanced renal cell carcinoma.

Publication types

  • News

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / physiopathology
  • Clinical Trials as Topic
  • Drug Delivery Systems
  • Humans
  • Indazoles
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / physiopathology
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology
  • Sulfonamides / therapeutic use*

Substances

  • Antineoplastic Agents
  • Indazoles
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Sulfonamides
  • pazopanib
  • Receptors, Vascular Endothelial Growth Factor